Royalty Report: Drugs, Cancer, Vaccine – Collection: 280951

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 9

Primary Industries

  • Drugs
  • Cancer
  • Vaccine
  • Therapeutic
  • Disease
  • Delivery
  • Diagnostic
  • Biotechnology
  • DNA
  • Pharmaceuticals
  • Immune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 280951

License Grant
The Canadian University grants to the Canadian Licensee an exclusive license, together with the right to grant sublicenses, in the territory for the field of use to practice the Patent Rights and otherwise use the Licensed Technology and to make, develop, use, import, offer to sell, sell, market and distribute and have made, developed, used, imported, offered to sell, sold, marketed and distributed Licensed Products.
License Property
Licensor has certain compositions and methods to elicit Thl immune response for use in vaccines.

BLP25 is a cancer vaccine being developed by Licensee containing a synthetic 25 amino acid sequence of the MUC-1 cancer mucin encapsulated in a liposomal delivery system and designed to induce an immune response to cancer cells.

Field of Use
The Field of use means any and all uses of the licensed technology in liposomal cancer vaccines.

IPSCIO Record ID: 256328

License Grant
This amendment revises the listed patents.  Per the restated agreement, Licensor grants and agrees to grant to Licensee, upon the terms and conditions set forth in this Agreement, the exclusive rights under the Licensed Intellectual Property to make, have made, use and sell Licensed Products and Licensed Processes throughout the world and otherwise to exploit the Licensed Intellectual Property commercially throughout the world.
License Property
With this amendment, the patents are expanded and include Whole Recombinant Yeast Vaccine Activates Dendritic Cells and Elicits Protective Cell-Mediated Immunity, and, Yeast Dendritic Cell Vaccines and Uses Thereof, and, Yeast-Antigen Compositions And Methods Of Making The Same.
Field of Use
Per the restated agreement, the field of use is research and investigation for cancer therapies.

IPSCIO Record ID: 28678

License Grant
The Canadian University hereby grants the Canadian Licensee an exclusive, royalty-bearing license in the Territory to practice the Licensed Technology and to make, develop, use, import, offer to sell, sell, market and distribute and have made, developed, used, imported, offered to sell, sold, marketed and distributed Licensed Product(s), until the end of the term of the last registered patent, at which time the license shall become a perpetual, fully-paid up, royalty-free license, unless this Agreement is sooner terminated according to the terms defined in this Agreement.
License Property
Licensee shall have the right to enter into sublicensing agreements for the rights, privileges and licenses granted in this Agreement but only with the prior written consent of University.

The University is the owner of certain Patent Rights (as later defined in this Agreement) relating to a technology developed by John Samuel and Glen Kwon, identified as UA IP# 94108 and described in the US Patent application No. 08/737,896 A Method for Eliciting a Thl Specific Immune Response (filed: September 24, 1997), which is a continuation-in-part of the US Patent application No. 08/480,499 (filed: June 7, 1995).

Patent Rights means all of the following UA intellectual property:
  (a)   the US Patent application No. 08/480,499 A Method for Eliciting a Thl Specific Immune Response (filed: June 7, 1995);

  (b)   the US Patent application No. 08/737,896 A Method for Eliciting a Thl Specific Immune Response (filed: September 24, 1997), a continuation-in-part of 1.6 (a) and later issued as US Patent No. 6,168,804 (issued: January 2, 2001);

  (c)   the US Patent application No. 09/668,825 A Method for Eliciting a Thl Specific Immune Response, a divisional application of 1.6 (b) (filed: September 22, 2000);

  (d)   any US divisional patent applications covering the invention disclosed in the patent application 1.6 (b) above and the resulting patents;
  (e)  any US continuation-in-part application, and the resulting patents, which are directed to the invention disclosed in the patent applications described in sections 1.6 (b), (c) and (d) above;
  (f)  any Canadian and foreign patent applications, and the resulting patents, which are based on the invention disclosed in the patent applications described in sections 1.6(e) above; and
  (g)  any reissues, extensions and divisions of Canadian and foreign patents described in sections 1.6 (b), (c), (d), (e) and (f) above.

Field of Use
Field of Use means any and all uses of microsphere formulations that infringe one or more claims contained in the Patent Rights for the treatment of infectious disease and cancer caused by chronic viral infection, including but not limited to hepatoma. (For greater certainty, the Field of Use does not include any use of the Patent Rights in liposomal cancer vaccines.)

IPSCIO Record ID: 249713

License Grant
Licensor grants to Licensee of the United Kingdom a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain any of the following two Licensed Antigens:
• Any and all ANTIGENS expressed in Prostate Cancer
• Any and all ANTIGENS expressed in Breast Cancer.

In further consideration of the obligations assumed by Licensee and subject to the terms and conditions of this Agreement, as of May 22, 2002 Licensee grants a non-exclusive license under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field any Products and/or Combinations in any formulation, composition or delivery systems which contain the following Licensed Antigens:
• Any and all Antigens expressed in Lung Cancer

License Property
The Product shall mean any and all pharmaceutical compositions for Prophylactic Immunization and/or Therapeutic Immunization in the field comprising one or more of the Licensed Antigens in combination with Adjuvant as an ingredient or component in any formulation, configuration, combination and/or delivery system, in which Adjuvant induces, augments, fine-tunes or enhances the Antigen specific immune response of any of such Licensed Antigens contained within Product.

The patents relate to Nucleic Acid and lmmunostimulatory methods and processes.

Field of Use
The Field shall mean the use of Adjuvant in combination with Licensed Antigens as part of a Product and/or Combination for the purpose of inducing, augmenting, fine-tuning or enhancing in vivo, in vitro or ex vivo of an Antigen specific immune response and in all cases for Prophylactic Immunization and/or Therapeutic Immunization against Licensed Cancers in humans, excluding Specific Field.

Specific Field shall mean without limitation the use of Adjuvant in combination with DNA Vaccines or other than in combination with a Licensed Antigen and independently from a Licensed Antigen or in combination with antibodies in passive immunotherapy applications when not combined with a tumor Antigen; or in all non Antigen specific ex vivo applications or for all purposes other than eliciting, inducing, augmenting, fine-tuning or enhancing an Antigen-specific immune response.

IPSCIO Record ID: 110461

License Grant
The University grants to Licensee and its Affiliates the exclusive license in the Territory with the right to grant sublicenses to others, under the Patent Rights, to make, have made, use, sell, import and offer for sale Products and to practice Processes.

Licensor grants to the Licensee the authority to make application for Patents, in the name of the Licensor.

License Property
The licensed patent applications relate to a Modified Heat Shock Protein-Antigenic Peptide Complex.
Field of Use
The licensed patent is in the area of the use of heat shock proteins for the development of therapeutic and prophylactic vaccines for cancer and infectious diseases (the 'Field').

IPSCIO Record ID: 279375

License Grant
The license granted by Licensor to Licensee shall be an exclusive license as to the agreed upon Field of Use, with a right to grant sublicenses, during the Term, to use, develop, make, have made, practice, import, carry out, manufacture, have manufactured, offer for sale, sell, offer for sale and/or have sold Products in the Field of Use in the Territory.
License Property
Products shall consist of any substance, device, apparatus or method covered in whole or in part by a Valid Claim useful to the diagnosis or treatment of disease or disorders utilizing a dendritic cell based vaccine for brain tumors and other cancers.
Field of Use
Field of Use is certain provisional patents and other proprietary intellectual property, relating to the work of Dr. John Yu with cellular therapies or diagnostics utilizing cellular therapies, including dendritic cell based vaccines for brain tumors and other cancers.  License is for a cancer vaccine therapy.

IPSCIO Record ID: 212650

License Grant
The Licensor grants to Licensee a non-exclusive, royalty-bearing license, with the right to grant sublicenses, under the Patents to Exploit the Licensed Product in the Field in the Territory and to Manufacture or have Manufactured the Compound in connection with such Exploitation of the Licensed Product.  Field shall mean the use of the Licensed Product for the prevention of infection by Hepatitis B Virus in humans.  Delivery Method for the Licensed Product shall mean intramuscular or subcutaneous delivery.
License Property
The Licensor is the owner or licensee of certain rights in proprietary technologies involving immunomodulatory oligonucleotides.

“Licensed Product” shall mean a prophylactic vaccine containing the Compound co-formulated with the Antigen for delivery by the Delivery Method. No Licensed Product(s) may be developed for the prevention, treatment or control of any cancer nor may any clinical trial be conducted with clinical endpoints of prevention, treatment or control of any cancer.

Patents Claiming Priority to Patent Application Serial No. 08/276,358

Field of Use
“Field” shall mean the use of the Licensed Product for the prevention of infection by Hepatitis B Virus in humans. The Field specifically excludes any product for the prevention of disease, indications or disorders other than Hepatitis B Virus in humans and any product for the treatment of any disease, indications or disorders.

IPSCIO Record ID: 28485

License Grant
The Licensee entered into an exclusive, worldwide License Agreement with a University for the AC Technology.
License Property
The AC Technology is based on the concept of haptenization.  

Our AC Technology utilizes the patient's tumor as the basis for a therapeutic vaccine.  By collecting and processing the cancer cells extracted from a patient's tumor most typically during the course of the first line of treatment, surgical tumor rescission, and then treating them with a hapten called dinitrophenol ('DNP'), a vaccine is prepared and then given back to the patient in an effort to elicit a systemic immune response to the unmodified, native cancer cells.

Field of Use
The Licensee is a development stage biotechnology company specializing primarily in the development and future commercialization of individualized cancer vaccines.  Our proposed vaccines consist of autologous (the patient's own) cancer cells that have been treated with a chemical ('haptenized') to make them more visible to the patient's immune system.  Our previous clinical trials for the AC Vaccine have concentrated on melanoma and ovarian carcinoma, which are our primary indications, and non-small cell lung cancer.

IPSCIO Record ID: 248332

License Grant
Licensor grants to Licensee a non-exclusive license, with the right to grant sublicenses, under the Technology, and to use the Immune Modulator in connection therewith, in each case to make, have made, use, have used, sell, have sold, offer for sale, and import Licensed Products in the Field in the Territory.
License Property
Licensor is the owner or licensee of certain rights, title, and interests in, and know-how related to, proprietary technologies involving immunomodulatory oligonucleotides.

Immune Modulator shall mean Coleys proprietary immunomodulatory oligonucleotide whose confidential sequence has been identified by Licensor as CpG 7909.

Licensed Product shall mean a product labeled for use in the Field and consisting of Immune Modulator, up to a maximum dose of 2 mg per administration, coformulated with one or more Antigens in a single vial; syringe or other suitable container.

VaxImmune™ is one member of Coley’s family of CpG TLR9 agonists, which are short synthetic DNA-like sequences that invoke potent innate and adaptive immune responses of the body’s immune system, comprised of both antibody- and cell-mediated pathways. Recent published scientific research by independent researchers have demonstrated that VaxImmune™ vaccine adjuvants are suitable for use in both prophylactic and therapeutic vaccines and can elicit a powerful immune response against infectious disease and cancers.

Field of Use
The Field shall mean the use of Immune Modulator co-formulated with one or more Antigens as a vaccine that is labeled solely for use as a prophylactic administered via a Specified Delivery Method to prevent one or more Specified Diseases in humans.

VaxImmune is known as a vaccine adjuvant, used in conjunction with a vaccine to improve immune responses and make the vaccine more effective.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.